The neuraminidase activity of influenza A virus determines the strain-specific sensitivity to neutralization by respiratory mucus.
influenza
mucus
neutralization
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
medline:
11
10
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
aheadofprint
Résumé
Respiratory mucus lining the airway epithelium constitutes an important first line of defense against infection with influenza A virus (IAV). Previous studies suggested that the inhibitory potential of mucus relies not only on the presence of decoy receptors but also on the dense meshwork blocking virus access to the epithelium independent of sialic acid. Here, we report for a panel of human and avian IAV isolates that susceptibility to neutralization by respiratory mucus varies in a strain-dependent manner. Our data reveal that viral neuraminidase (NA) activity inversely correlates with the mucus sensitivity of a given strain. As NA cleaves sialic acid from glycan chains and thus releases IAV from decoy receptor binding, our results imply that virus inhibition by mucus is mainly driven by decoy receptor binding of IAV. Other inhibitory properties of mucus, such as size exclusion, non-covalent interactions with mucus components, or the presence of immunomodulatory molecules, likely play minor roles in neutralizing IAV. Inhibition of NA activity using oseltamivir was sufficient to increase the sensitivity of a seasonal IAV strain to mucus during infection in a cell-based neutralization assay and in differentiated primary human airway epithelial cultures. Overall, our data highlight the importance of NA for the initiation of virus infection besides its major function in release, especially in overcoming the host defense mechanism of mucociliary clearance in the airway epithelium. Furthermore, strain-specific differences in the ability to penetrate respiratory mucus may be the result of host adaptation and can have consequences for the transmissibility and infectivity of circulating viruses. IMPORTANCE The respiratory tract of humans is constantly exposed to potentially harmful agents, such as small particles or pathogens, and thus requires protective measures. Respiratory mucus that lines the airway epithelia plays a major role in the prevention of viral infections by limiting the mobility of viruses, allowing subsequent mucociliary clearance. Understanding the interplay between respiratory mucus and viruses can help elucidate host and virus characteristics that enable the initiation of infection. Here, we tested a panel of primary influenza A viruses of avian or human origin for their sensitivity to mucus derived from primary human airway cultures and found that differences between virus strains can be mapped to viral neuraminidase activity. We also show that binding of influenza A viruses to decoy receptors on highly glycosylated mucus components constitutes the major inhibitory function of mucus against influenza A viruses.
Identifiants
pubmed: 37819131
doi: 10.1128/jvi.01271-23
pmc: PMC10617592
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0127123Références
Microbes Infect. 2006 Apr;8(5):1287-93
pubmed: 16682242
J Virol. 2002 Apr;76(8):3756-64
pubmed: 11907215
J Biol Chem. 2003 Nov 28;278(48):48245-50
pubmed: 14500706
FASEB J. 2009 Jun;23(6):1858-68
pubmed: 19190083
Viruses. 2019 Jan 11;11(1):
pubmed: 30641890
PLoS One. 2012;7(3):e32857
pubmed: 22412934
Trends Microbiol. 2019 Jun;27(6):477-479
pubmed: 30930001
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16528-33
pubmed: 23012413
Biomaterials. 2013 Apr;34(13):3439-46
pubmed: 23384790
Science. 1994 Jun 24;264(5167):1918-21
pubmed: 8009221
Virology. 1983 Jun;127(2):361-73
pubmed: 6868370
EMBO J. 2014 Apr 16;33(8):823-41
pubmed: 24668228
J Gen Virol. 1971 Aug;12(2):161-8
pubmed: 4107843
J Infect Dis. 2018 Jul 24;218(5):739-747
pubmed: 29878137
Biometals. 2010 Jun;23(3):465-75
pubmed: 20232110
Tissue Barriers. 2013 Oct 1;1(4):e24997
pubmed: 24665407
mSphere. 2020 Aug 26;5(4):
pubmed: 32848003
Trends Microbiol. 2021 Nov;29(11):983-992
pubmed: 33875348
FEBS J. 2021 Oct;288(19):5598-5612
pubmed: 33314755
Nat Biotechnol. 2009 Sep;27(9):797-9
pubmed: 19741625
Eur Respir J. 2017 Jan 25;49(1):
pubmed: 28122865
Eur Respir J. 2004 Feb;23(2):327-33
pubmed: 14979512
Cell Host Microbe. 2016 Feb 10;19(2):159-68
pubmed: 26867175
Acta Histochem Suppl. 1990;40:35-8
pubmed: 2091044
Elife. 2019 May 14;8:
pubmed: 31084711
Glycobiology. 2005 Aug;15(8):747-75
pubmed: 15994837
Virology. 1974 Oct;61(2):397-410
pubmed: 4472498
Virol J. 2013 Nov 22;10:321
pubmed: 24261589
Nature. 1946 Mar 2;157:263
pubmed: 21016866
Virology. 1998 Aug 1;247(2):223-31
pubmed: 9705915
Virology. 1962 Apr;16:466-78
pubmed: 14449377
Chest. 2018 Jul;154(1):169-176
pubmed: 29170036
Int Rev Cell Mol Biol. 2013;303:139-202
pubmed: 23445810
Phys Rev Lett. 2021 May 28;126(21):218101
pubmed: 34114881
Trends Cell Biol. 2011 Sep;21(9):543-51
pubmed: 21727007
Virus Res. 1993 Aug;29(2):155-65
pubmed: 8212857
Nature. 1988 Jun 2;333(6172):426-31
pubmed: 3374584
Commun Biol. 2022 Mar 22;5(1):249
pubmed: 35318436
J Mol Biol. 2006 Feb 3;355(5):1143-55
pubmed: 16343533
Glycobiology. 1999 Mar;9(3):311-21
pubmed: 10024669
Virology. 1963 Oct;21:278-81
pubmed: 14070184
Science. 2021 Aug 27;373(6558):
pubmed: 34446582
mBio. 2020 Sep 10;11(5):
pubmed: 32913009
Rev Med Virol. 2002 May-Jun;12(3):159-66
pubmed: 11987141
Int J Mol Sci. 2017 Jul 17;18(7):
pubmed: 28714909
J Virol. 2004 Nov;78(22):12665-7
pubmed: 15507653
Nature. 2013 Nov 14;503(7475):218-23
pubmed: 24196716
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7306-11
pubmed: 23589850
Trends Microbiol. 2020 Jan;28(1):57-67
pubmed: 31629602
J Virol. 2015 Mar;89(6):3136-44
pubmed: 25552718
PLoS One. 2014 Oct 15;9(10):e110026
pubmed: 25333824
J Virol. 2013 Oct;87(19):10539-51
pubmed: 23864615
PLoS Biol. 2021 Mar 24;19(3):e3001006
pubmed: 33760807
Mucosal Immunol. 2013 Mar;6(2):379-92
pubmed: 22929560
J Virol. 2000 Dec;74(24):11825-31
pubmed: 11090182
Respir Res. 2007 Oct 25;8:73
pubmed: 17961210
J Virol. 2013 Dec;87(24):13343-53
pubmed: 24089563
Nature. 1992 Jun 4;357(6377):420-2
pubmed: 1350662
Environ Sci Technol. 2023 Jan 10;57(1):486-497
pubmed: 36537693
PLoS Pathog. 2018 Aug 13;14(8):e1007233
pubmed: 30102740